Patents Assigned to Genfit
  • Method for NASH risk assessment
    Patent number: 12638460
    Abstract: The present invention relates to a new assay to diagnose nonalcoholic steatohepatitis (NASH), NASH progression and NASH fibrosis stage.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: May 26, 2026
    Assignee: GENFIT
    Inventors: Zouher Majd, Pierre Chaumat
  • Compositions and methods for the treatment of primary biliary cholangitis
    Patent number: 12589086
    Abstract: The invention relates to a pharmaceutical composition comprising elafibranor or a pharmaceutically acceptable salt thereof, for use to treat primary biliary cholangitis (PBC) in a subject intolerant to ursodeoxycholic acid (UDCA).
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: March 31, 2026
    Assignee: Genfit
    Inventors: Pascal Birman, Alice Roudot, David Magrez, Benoit Noel
  • Polymorphs of elafibranor
    Patent number: 12522564
    Abstract: The present invention relates to novel crystalline forms of elafibranor.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: January 13, 2026
    Assignee: GENFIT
    Inventors: Karine Bertrand, Jean-François Delhomel, Alice Roudot
  • Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists
    Patent number: 12458612
    Abstract: The present invention relates to a combination therapy comprising a PPAR agonist, such as elafibranor, and a GLP-1 receptor agonist, such as semaglutide, liraglutide, exenatide, lixisenatide, albiglutide and dulaglutide, for the treatment of a condition is selected from the group consisting of non-alcoholic fatty liver disease, diabetes and obesity.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: November 4, 2025
    Assignee: GENFIT
    Inventors: Robert Walczak, Vanessa Legry, Emeline Descamps
  • Phosphate derivatives of RORgamma modulators and uses thereof
    Patent number: 12391712
    Abstract: The present invention relates to phosphate derivatives of formula (I), and their therapeutic uses, preferably for treating a respiratory disease. The present invention further relates to pharmaceutical compositions and devices comprising such compounds.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: August 19, 2025
    Assignee: GENFIT
    Inventors: Jean-François Delhomel, Robert Walczak, Peggy Parroche, Anne-Marie Saveret
  • Methods of treatment of cholestatic diseases
    Patent number: 12310935
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: November 9, 2023
    Date of Patent: May 27, 2025
    Assignee: Genfit
    Inventor: Remy Hanf
  • Methods of treatment of cholestatic diseases
    Patent number: 12295928
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5 -dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: November 9, 2023
    Date of Patent: May 13, 2025
    Assignee: Genfit
    Inventor: Remy Hanf
  • Methods of treatment of cholestatic diseases
    Patent number: 12295927
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: November 9, 2023
    Date of Patent: May 13, 2025
    Assignee: Genfit
    Inventor: Remy Hanf
  • Methods of treatment of cholestatic diseases
    Patent number: 12290498
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: November 9, 2023
    Date of Patent: May 6, 2025
    Assignee: Genfit
    Inventor: Remy Hanf
  • Methods of treatment of cholestatic diseases
    Patent number: 12233038
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: November 9, 2023
    Date of Patent: February 25, 2025
    Assignee: Genfit
    Inventor: Remy Hanf
  • Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
    Patent number: 12208087
    Abstract: The present invention relates to a combination product comprising (i) nitazoxanide (NTZ) or an analogue thereof, and (ii) a PPAR agonist, for use in the treatment of an immune diseases or inflammation.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: January 28, 2025
    Assignee: GENFIT
    Inventors: Peggy Parroche, Robert Walczak
  • Non-invasive diagnostic of non-alcoholic steatohepatitis
    Patent number: 12104209
    Abstract: The invention relates to a novel method for the diagnosis of non-alcoholic steatohepatitis (NASH), and for classifying a subject as a potential receiver of a treatment for NASH.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: October 1, 2024
    Assignee: GENFIT
    Inventors: Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • Methods of treatment of cholestatic diseases
    Patent number: 12053445
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: August 6, 2024
    Assignee: GENFIT
    Inventor: Remy Hanf
  • Pharmaceutical compositions for combination therapy
    Patent number: 12053456
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: August 6, 2024
    Assignee: GENFIT
    Inventors: Corinne Foucart, Robert Walczak, Carole Belanger, Benoît Noel
  • NITAZOXANIDE IN THE TREATMENT OF SEPSIS
    Publication number: 20240238256
    Abstract: The present invention relates to a compound selected from nitazoxanide, tizoxanide and tizoxanide glucuronide, for use in a method for the treatment of sepsis in a subject in need thereof.
    Type: Application
    Filed: May 10, 2022
    Publication date: July 18, 2024
    Applicant: GENFIT
    Inventors: Vanessa LEGRY, Rémy HANF, Simon DEBAECKER
  • Elafibranor salts
    Patent number: 12030840
    Abstract: The present invention relates to salts of elafibranor.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 9, 2024
    Assignee: GENFIT
    Inventors: Karine Bertrand, Alice Roudot, Marie-Jeanne Joissains
  • RORgamma modulators and uses thereof
    Patent number: 11974997
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: May 7, 2024
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • Methods of treatment of cholestatic diseases
    Patent number: 11857523
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: January 2, 2024
    Assignee: Genfit
    Inventor: Remy Hanf
  • Methods of treatment of cholestatic diseases
    Patent number: 11850223
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: December 26, 2023
    Assignee: Genfit
    Inventor: Remy Hanf
  • Automated pattern recognition and scoring method of histological images
    Patent number: 11676269
    Abstract: The present invention relates to a novel automated pattern recognition and scoring method of histological images.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: June 13, 2023
    Assignee: GENFIT
    Inventors: John Brozek, Nathalie Degallaix, Benoit Noel, Elton Rexhepaj